Health Problems

Zimhi

Zimhi

Adamis Pharmaceuticals Resubmits Zimhi New Drug Application to FDA for the Treatment of Opioid Overdose

mobocertinib

mobocertinib

mobocertinib Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788)

maralixibat

maralixibat

maralixibat Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome FOSTER